No bad stock

Edwards Lifesciences Corporation
CEO : Mr. Michael A. Mussallem

Quarterly earnings growth(YoY,%)

Scott Ullem says,

Q4 2022 Financial Results

• Sales in Q4 2022 grew 7% on a constant currency basis to $1.3 billion despite healthcare disruptions in key geographies.
• Adjusted earnings per share grew by 25% to $0.64.
• Sales for the full year 2022 increased 8% on a constant currency basis to $5.4 billion, and adjusted earnings per share grew 12%.
• Average shares outstanding during Q4 was $616 million.

Stock Repurchase

• Repurchased $750 million of stock through an accelerated share repurchase program in Q4 2022.
• Repurchased $1.7 billion of stock in 2022.
• Approximately $900 million remaining under the current share repurchase authorization.

Sales Guidance

• Expect sales growth rate to expand in 2023 with a gradual improvement in hospital staffing.
• Maintaining all previous sales guidance ranges for 2023 with total company sales of $5.6 billion to $6 billion, TAVR sales of $3.6 billion to $4 billion, TMTT sales of $160 million to $200 million, Surgical Structural Heart sales of $870 million to $970 million, and critical care sales of $840 million to $940 million.
• Projecting sales of $1.37 billion to $1.45 billion and adjusted earnings per share of $0.58 to $0.64 for Q1 2023.

Financial Outlook

• Expect full year 2023 adjusted gross profit margin to be between 76% and 78%.
• Expect full year 2023 SG&A expenses as a percent of sales to be between 29% and 30%.
• Expect R&D expenses in 2023 to be between 17% and 18% of sales.
• Expect 2023 tax rate, excluding special items, to be 13% to 17%.
• Expect free cash flow to grow to $1.0 billion to $1.4 billion in 2023.

Mark Wilterding says,

Edwards Lifesciences Q4 2022 Earnings Call Summary

• Edwards Lifesciences released their Q4 2022 financial results after the close of regular trading
• Management will be making forward-looking statements based on estimates, assumptions, and projections
• Financial guidance and expectations for longer-term growth opportunities, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters, and foreign currency fluctuations will be discussed
• The statements involve risks and uncertainties that could cause actual results to differ materially
• Information concerning factors that could cause these differences and important product safety information may be found in the press release and SEC filings

Q & A sessions,

Revenue Growth

• The quarter is expected to show significant revenue growth compared to the previous year’s quarter.
• The company has reported growth in both their core business and new ventures.

Guidance

• The company is expected to provide strong guidance for the upcoming year.
• The guidance is expected to include plans for continued investment in new ventures and potential acquisitions.

Cost Management

• The company has implemented cost management initiatives to improve efficiency and profitability.
• These initiatives are expected to contribute to improved margins and bottom-line results.

Changes in Leadership

• The company has recently undergone changes in its leadership team.
• The impact of these changes on the company’s performance and strategy is yet to be fully realized.

Impact of COVID-19

• The company has adapted to the challenges posed by the pandemic and continued to operate successfully.
• The impact of ongoing COVID-19 developments on the company’s future performance is uncertain.